<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05023928</url>
  </required_header>
  <id_info>
    <org_study_id>ESOC2108</org_study_id>
    <nct_id>NCT05023928</nct_id>
  </id_info>
  <brief_title>Tumor Antigen-sensitized DC Vaccine as an Adjuvant Therapy for Esophagus Cancer</brief_title>
  <official_title>Research on the Transformation of Postoperative Adjuvant Therapy of Tumor Antigen-sensitized DC Vaccine Applied to Esophagus Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this single center, single arm and prospective study is to explore the safety and&#xD;
      efficacy of tumor antigen-sensitized DC vaccine in postoperative adjuvant treatment of&#xD;
      esophageal cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as events as assessed by CTCAE v4.0</measure>
    <time_frame>3 months after the last administration of cells</time_frame>
    <description>Number of participants with treatment-related adverse events as events as assessed by CTCAE v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Number of participants with Disease-free Survival as assessed by RECIST1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Carcinoma</condition>
  <condition>Esophagus Cancer</condition>
  <arm_group>
    <arm_group_label>Tumor antigen-sensitized DC vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tumor antigen-sensitized vaccine is administrated, 1-week interval, totally 2 times.&#xD;
2-week later, Neo-antigen DC vaccine is administrated, 2-week interval, totally 5 times.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tumor antigen-sensitized DC vaccine</intervention_name>
    <description>subcutaneous administration</description>
    <arm_group_label>Tumor antigen-sensitized DC vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed diagnosis of esophageal squamous cell carcinoma；&#xD;
&#xD;
          -  Immunotherapy for preoperative；&#xD;
&#xD;
          -  Karnofsky performance status 0-1;&#xD;
&#xD;
          -  The postoperative pathological stage is (y) Pt + and / or N + M0 according to AJCC 8th&#xD;
&#xD;
          -  Function of the main organs is normal;&#xD;
&#xD;
          -  Edition Patient's written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumor emergencies;&#xD;
&#xD;
          -  Abnormal coagulation function;&#xD;
&#xD;
          -  Contagious diseases, such as HIV, HBV, HCV infection;&#xD;
&#xD;
          -  Mental disorders;&#xD;
&#xD;
          -  Concomitant tumors;&#xD;
&#xD;
          -  Immunological co-morbidities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhen-Yu Ding, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sichuan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhen-Yu Ding, Prof</last_name>
    <email>dingzhenyu@scu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhen-Yu Ding, Prof</last_name>
      <phone>0086288542357</phone>
      <email>dingzhenyu@scu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 21, 2021</study_first_submitted>
  <study_first_submitted_qc>August 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>August 21, 2021</last_update_submitted>
  <last_update_submitted_qc>August 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan University</investigator_affiliation>
    <investigator_full_name>Zhen-Yu Ding</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>esophagus cancer</keyword>
  <keyword>tumor neo-antigen DC vaccine</keyword>
  <keyword>safety</keyword>
  <keyword>clinical efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

